Skip to main content

Advertisement

Table 2 Comparison of median and interquartile range of plasma efavirenz (EFV) concentrations (mg/L) between HIV patients receiving EFV based HAART only and TB-HIV coinfected patients receiving EFV based HAART with rifampicin (RIF) based TB therapy

From: Influence of efavirenz pharmacokinetics and pharmacogenetics on neuropsychological disorders in Ugandan HIV-positive patients with or without tuberculosis: a prospective cohort study

   Treatment group p
  EFV only   EFV + RIF
N Median (IQR) N Median (IQR)
Day-3 57 2.48 (1.85-2.92) 107 1.85 (1.34-2.86) 0.02
week-1 53 2.37 (1.92-3.18) 57 1.80 (1.34-2.49) 0.01
week-2 53 2.21 (1.63-3.21) 100 1.94 (1.38-2.60) 0.21
week-4 49 2.45 (1.73-3.22) 103 1.87 (1.43-3.13) 0.48
week-6 38 2.37 (1.70-3.51) 86 1.89 (1.63-4.19) 0.93
week-8 50 2.41 (1.64-3.06) 118 1.82 (1.42-3.21) 0.40
week-12 44 2.41 (1.65-3.55) 101 2.04 (1.47-3.64) 0.69
  1. Plasma efavirenz concentrations were monitored at day 3 and at 1, 2, 4, 6, 7, 8 and 12 weeks after starting efavirenz based HAART. For statistical analysis, Log transformed efavirenz concentration was used using independent sample T-test.